GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine. Results from a second larger full dose trial also indicate a good safety profile in participants. The GeoVax vaccines being tested are designed to prevent the development of Acquired Immunodeficiency Disease ("AIDS") caused by the virus known as HIV-1 by vaccinating individuals prior to infection with the AIDS virus.

Early results from GeoVax's preventative HIV/AIDS vaccine human trials:

• Demonstrate a very acceptable safety profile in an ongoing 1/10th dose trial begun in April, 2006

• ndicate that as low as 1/10th of a full dose of GeoVax's HIV/AIDS vaccine stimulates potentially protective anti-HIV-1 immune responses in the majority of vaccine recipients

• Suggest an acceptable safety profile in an ongoing full dose trial begun Sept 2006

• Suggest that a full dose of the vaccine will stimulate an even better immune response in recipients participating in the full dose trial; data is expected later in 2007

• Support accelerated planning for a large Phase II human trial including more than 300 participants across North and South America and the Caribbean and with an earlier start date than originally anticipated

The 1/10th dose trial, begun April, 2006, is evaluating GeoVax's AIDS vaccines primarily for their safety and potential efficacy as a preventative vaccine administered to people prior to infection with the HIV-1 virus, thus preventing the development of AIDS. A positive human immune response to the vaccine is indicated by the presence of antibodies and T cells (white blood cells) that recognize and co
'"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
Financial Relations Board
6-Feb-2007